C&G Editor in Chief, Erin Harris
-
The Case For CGT In-House Manufacturing
3/31/2023
With flexible and sustainable design strategies and best practices and contingency planning based on current market conditions and exit strategies, building an in-house facility is feasible.
-
The CureDuchenne, Sarepta Therapeutics Partnership
3/28/2023
CureDuchenne is a non-profit located in Newport Beach, CA, that focuses on supporting translational research with the aim of getting promising therapies out of the labs and into human trials as fast and as safely as possible and has partnered with Sarepta from its earliest stages. I caught up with Michael G. Kelly, Ph.D., Chief Scientific Officer at CureDuchenne to learn more about the organization and its partnership with Sarepta.
-
CGT’s Highly Anticipated Regulatory Decisions
3/17/2023
Time is flying, and as 2023 marches on, as many as 13 cell or gene therapies could be granted FDA approval by the end of the year.
-
A Breakdown Of Scaling Cell Therapies Part 2
3/9/2023
Our Cell & Gene Live, Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing, aired last month and is now available on demand. Here is a breakdown of the full 60-minute presentation into smaller segments so you can learn at your own pace.
-
Rare Disease Day 2023
2/28/2023
Rare Disease Day 2023 is upon us, and SwanBio's Karen Kozarsky weighs in on progress in gene therapy.
-
Cell & Gene: The Podcast Covers CGT Companies in the News
2/23/2023
Sangamo Therapeutics, Mustang Bio, Cartesian Therapeutics and more have been in the news recently. Here's an update on what they've released as well as the Cell & Gene: The Podcast episodes that provide the important details that led to their the announcements.
-
Modernizing Efficient Payment Structures For CGTs
2/22/2023
Can the various stakeholders in the CGT sector modernize efficient payment structures quickly enough to keep pace with the science? The questions are complicated, the options are complicated, and so, too, are the potential solutions.
-
CGT’s Top Regulatory Challenges Broken Down By Segment
1/31/2023
Our recent Cell & Gene Live, Tackling Cell & Gene Therapies’ Top 3 Regulatory Impediments, featuring BridgeBio's Dr. Adora Ndu and REGENXBIO's Dr. Nina Hunter, delivered just under 60 minutes of exceptionally valuable information. We also know that your time is likely not your own, which is why we’ve broken down the full-length version into digestible segments that you can view on your own time.
-
XyloCor’s Phase 2 EXACT Trial Success
1/31/2023
XyloCor Therapeutics’ CEO, Albert Gianchetti provides updates about the clinical-stage biopharma’s EXACT clinical trial.
-
Astellas Pharma: Moving On from Clinical Hold
1/26/2023
Ha Tran, Executive Medical Director at Astellas Pharma, explains the cause of the clinical hold and the future of the program now that the hold has been lifted.